What Is Major Depressive Disorder? Symptoms, Diagnosis, and Treatment

Major depressive disorder has effective treatments. That fact does not fully capture the clinical reality, which is that most people with MDD either go undiagnosed, stop treatment before it works, or never receive the level of monitoring that makes a difference.

Understanding what MDD actually is, how it is diagnosed, and what the evidence says about treating it gives patients the foundation to have better conversations with their care team and to recognize the difference between a medication that is not working and one that has not had time to work yet.

What This Page Covers

• What major depressive disorder is and how it differs from ordinary sadness
• The DSM-5 diagnostic criteria in plain language
• How MDD is diagnosed and what the evaluation involves
• The symptoms most frequently missed
• First-line treatments and what the evidence shows
• What treatment resistance means and what comes next
• Why ongoing monitoring changes outcomes

What Major Depressive Disorder Is

Major depressive disorder is not a personality trait or a reaction to circumstances. It is a clinical syndrome involving mood, cognition, sleep, appetite, energy, and physical functioning that persists for at least two weeks and causes significant impairment in daily life.

MDD is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. Five of these symptoms must be present for at least two weeks, and at least one must be either depressed mood or loss of interest.

About 21.4 million people experienced a major depressive episode in 2024. Among adults ages 18 to 25, the rate is nearly twice the overall adult average. Major depression became the second leading cause of worldwide disability by 2013, both globally and in the United States.

The DSM-5 Criteria: What Clinicians Are Looking For

The nine diagnostic criteria for a major depressive episode are:

1. Depressed mood most of the day, nearly every day (in children and adolescents, this may be irritable mood)
2. Markedly diminished interest or pleasure in all, or almost all, activities
3. Significant weight change (more than 5% in a month) or change in appetite
4. Insomnia or hypersomnia nearly every day
5. Psychomotor agitation or slowing observable by others
6. Fatigue or loss of energy
7. Feelings of worthlessness or excessive guilt
8. Diminished ability to think, concentrate, or make decisions
9. Recurrent thoughts of death, suicidal ideation, or a suicide attempt

Per the DSM-5, an individual must have five of the above-mentioned symptoms, of which one must be a depressed mood or anhedonia, causing social or occupational impairment. A history of manic or hypomanic episodes must be ruled out, as that pattern points toward bipolar disorder rather than MDD.

Symptoms Most Frequently Missed

Patients often underreport certain criteria because they do not connect them to depression. Psychomotor slowing: speaking more slowly, moving more deliberately, taking longer to respond. Anhedonia is often described as flatness rather than sadness: an inability to feel engaged in activities that used to matter. Concentration difficulty shows up as missed deadlines, forgetting conversations, and an inability to read for sustained periods.

Sleep changes are typically reported. Appetite changes and fatigue often get attributed to stress, aging, or a busy schedule. When several symptoms are being explained away, the clinical picture is incomplete and the right conversation does not happen.

How MDD Is Diagnosed

There is no blood test or brain scan that diagnoses MDD. Diagnosis is clinical: a trained provider reviews symptoms, duration, severity, and functional impact through a structured interview.

The PHQ-9 is the most widely used screening and monitoring tool. Its nine items mirror the DSM-5 criteria. A score of 10 or higher suggests clinically significant depression. It is not a diagnostic tool on its own, but it structures the conversation and gives both the clinician and the patient a quantified baseline for tracking treatment response.

A complete evaluation also rules out medical causes of depressive symptoms: hypothyroidism, anemia, certain medications (beta blockers, corticosteroids, some hormonal contraceptives), and neurological conditions. Bipolar disorder must be distinguished from MDD, as the presence of a past hypomanic or manic episode changes both the diagnosis and the treatment approach.

Depressive disorders occur at any age but typically develop during the mid teens, 20s, or 30s, with an average age of onset of 29 years for MDD in the United States. Women are diagnosed at higher rates than men across most age groups.

First-Line Treatments: What the Evidence Shows

Medications

Bupropion, escitalopram, mirtazapine, paroxetine, sertraline, and extended-release venlafaxine are the most effective medications for treatment of major depressive disorder, according to the 2025 CANMAT guidelines. These are primarily SSRIs and SNRIs, which are considered first-line agents.

A critical clinical benchmark: without an early improvement of 20% symptom reduction or more by four weeks of pharmacotherapy, there is a low likelihood of treatment response or remission at 8 to 12 weeks. The antidepressant medication should be switched or the dose increased in these patients. This is why the four-week mark matters. Waiting passively through three months on a medication that is not working costs time that could be spent finding one that does.

Most antidepressants require four to eight weeks to reach full effect. Starting at a low dose and titrating gradually is standard. Side effects like GI distress, insomnia, and sexual side effects are common in the first few weeks and often diminish. Sustained or worsening side effects should be reported to your prescriber rather than treated as reasons to stop unilaterally.

Psychotherapy

For most patients, psychotherapy should include 12 to 16 sessions twice weekly for best results. Cognitive behavioral therapy (CBT) is the best-studied psychotherapy for MDD. It addresses thought patterns that maintain depression and builds behavioral activation and coping skills.

Combined treatment, medication plus psychotherapy, consistently outperforms either alone for moderate to severe MDD. The combination is particularly important for patients with significant comorbidities, a trauma history, or high relapse risk.

Exercise

Supervised low- to moderate-intensity exercise for 30 to 40 minutes three to four times per week for a minimum of nine weeks is a first-line monotherapy for mild depression. This is a genuine clinical recommendation, not a lifestyle suggestion. For mild to moderate MDD, exercise has an evidence base as a standalone intervention. Adherence is the primary challenge.

What Treatment Resistance Means

Not everyone responds to the first antidepressant. The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had treatment-resistant depression. TRD is generally defined as failure to respond to at least two adequate antidepressant trials.

When TRD emerges, options include switching to a different medication class, augmentation (adding lithium, atypical antipsychotics, or thyroid hormone), and neuromodulation treatments including TMS and esketamine. About 35% of people with major depression do not respond to standard antidepressants.

Recognizing treatment resistance earlier, rather than after three or four failed trials, keeps more options available. This is one clinical reason why the four-week benchmark matters: it shortens the time between identifying a non-response and doing something about it.

Why Outcomes Depend on What Happens After the First Appointment

MDD has effective treatments. The gap between available treatments and sustained recovery comes down to what happens between appointments.

Most patients have quarterly check-ins at best. Between those appointments, side effects emerge, motivation drops, life disrupts the routine, and the “I feel better so I can stop” impulse arrives weeks before it is clinically appropriate. By the next appointment, the window for easy intervention has often closed.

Daily monitoring closes that window. A licensed prescriber who sees your mood trajectory, medication adherence, and side effect pattern in real time can act on the four-week signal, not just summarize the past three months.

“The four-week benchmark is something we can only act on if we’re actually watching at week four,” says Daniel Montville, MD, Psychiatrist of the SiggyMD clinical team. “Most patients do not have that visibility. If no one is checking, no one can tell you it’s time to change course.”

About SiggyMD

SiggyMD provides clinician-reviewed treatment plans for depression and anxiety, with daily check-ins that track mood, medication adherence, side effects, and progress between appointments. The AI intake gathers clinical information; a licensed prescriber reviews and approves every treatment decision. Nothing is prescribed without that clinical oversight.

If you are experiencing symptoms consistent with depression and want to start a clinical conversation, start your anonymous intake with SiggyMD. No account, no email, no name required to begin.

You can also read more about what happens when a first antidepressant is not producing results: Antidepressant Not Working? 3 Patterns Clinicians Look For Before Switching.

What Members Are Saying

AK

A.K., 33

Major Depressive Disorder

“I had been on the same SSRI for two years and telling myself it was working because I was functioning. When I started doing daily check-ins, my prescriber could see my mood scores were consistently low and I was still having most of my symptoms. We switched medications and within six weeks I felt genuinely different. I did not know how much better I could feel.”

MS

M.S., 47

Recurrent Major Depressive Disorder

“I have had three major episodes. The difference with this approach is that I do not have to wait three months to tell someone things are getting worse. The check-in takes two minutes. My prescriber sees the trend. This time we caught the relapse early enough to adjust before it became severe.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

The Bottom Line

Major depressive disorder is a clinical syndrome with specific criteria, a robust evidence base for treatment, and a well-understood pattern of risk when undertreated. The gap between available treatments and what patients actually experience comes down to monitoring and adherence.

Getting a diagnosis and a prescription is the beginning of treatment. What determines long-term outcomes is whether someone is tracking their response, adjusting when the early signals say to adjust, and staying in treatment through the period when most people drop off.

Sources

1. Hasin DS, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018;75(4):336-346.

2. American Psychological Association. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. APA. 2019.

3. American Academy of Family Physicians. Management of Major Depressive Disorder in Adults: Guidelines From CANMAT. Am Fam Physician. 2025;112(4):458-461.

4. Zhdanava M, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021;82(2).

5. Merck Manual. Depressive Disorders. Accessed June 2026.

6. National Library of Medicine. PHQ-9. StatPearls. Updated 2024.

7. Innerwell. Mental Health Statistics 2026. Accessed June 2026.

8. National Institute of Mental Health. Major Depression. NIMH. Updated 2024.